Scientists may have discovered a cure for baldness – but there's a catch
1/5
Researchers at San Carlos Clinical Hospital in Madrid have developed a cure for androgenetic alopecia, commonly known as pattern hair loss.
An estimated 80 million Americans – 50 million men and 30 million women – experience some form of alopecia, although it affects women differently than men.
Men usually go through a receding hairline and bald spots, whereas women get thinner at the part line but rarely go fully bald.
In the study – published in the journal Stem Cell Research and Therapy – researchers used a combo of fat‑tissue-derived stem cells and the energy molecule ATP to reverse hair loss in mice, with shocking results.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Courier-Mail
9 hours ago
- Courier-Mail
Scientists may have discovered a cure for baldness – but there's a catch
1/5 Researchers at San Carlos Clinical Hospital in Madrid have developed a cure for androgenetic alopecia, commonly known as pattern hair loss. An estimated 80 million Americans – 50 million men and 30 million women – experience some form of alopecia, although it affects women differently than men. Men usually go through a receding hairline and bald spots, whereas women get thinner at the part line but rarely go fully bald. In the study – published in the journal Stem Cell Research and Therapy – researchers used a combo of fat‑tissue-derived stem cells and the energy molecule ATP to reverse hair loss in mice, with shocking results.
Sydney Morning Herald
13 hours ago
- Sydney Morning Herald
Proteomics flags US rollout of kidney test at global diabetes summit
ASX-listed diagnostics disruptor Proteomics International has officially launched its innovative kidney disease test, PromarkerD, in the massive United States healthcare market. The launch took place at the American Diabetes Association's 85th scientific sessions talkfest in Chicago. The annual conference marks the world's largest gathering of diabetes experts, making it the ideal stage to unveil PromarkerD to the US market. PromarkerD is a simple predictive blood test capable of identifying a person's risk of developing diabetic kidney disease (DKD) up to four years before symptoms appear, offering a potential lifeline to the more than 32 million Americans living with type 2 diabetes. According to clinical studies, the patented test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms. 'This marks a significant milestone in our global commercialisation strategy.' Proteomics International managing director Dr Richard Lipscombe More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'We're excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.' The PromarkerD rollout will begin in California, supported by the company's recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International's integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement. Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test 'a paradigm shift in diabetes care.' Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.
The Age
13 hours ago
- The Age
Proteomics flags US rollout of kidney test at global diabetes summit
ASX-listed diagnostics disruptor Proteomics International has officially launched its innovative kidney disease test, PromarkerD, in the massive United States healthcare market. The launch took place at the American Diabetes Association's 85th scientific sessions talkfest in Chicago. The annual conference marks the world's largest gathering of diabetes experts, making it the ideal stage to unveil PromarkerD to the US market. PromarkerD is a simple predictive blood test capable of identifying a person's risk of developing diabetic kidney disease (DKD) up to four years before symptoms appear, offering a potential lifeline to the more than 32 million Americans living with type 2 diabetes. According to clinical studies, the patented test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms. 'This marks a significant milestone in our global commercialisation strategy.' Proteomics International managing director Dr Richard Lipscombe More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'We're excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.' The PromarkerD rollout will begin in California, supported by the company's recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International's integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement. Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test 'a paradigm shift in diabetes care.' Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.
